FDA approves first medication for obstructive sleep apnea — which also promotes weight loss

Core Insights - The FDA has approved Eli Lilly's Zepbound (tirzepatide) as the first medication for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, marking a significant advancement in treatment options for this condition [3][4][5] Drug Approval and Mechanism - Zepbound is intended to be used alongside a reduced-calorie diet and increased physical activity, which is essential for its effectiveness [3][6] - The drug works by activating receptors of hormones secreted from the intestine (GLP-1 and GIP), similar to other treatments like semaglutide [3][5] Patient Impact and Statistics - Approximately 30 million people in the US suffer from sleep apnea, with obesity being a common contributing factor [6] - Studies indicate that Zepbound leads to a statistically significant reduction in apnea or hypopnea events, with many participants achieving remission or resolution of symptoms [7] Expert Opinions - Experts view the approval as a promising advancement for patients, particularly for those who struggle with traditional therapies like positive airway pressure (PAP) [5] - The drug is seen as a potential generational medication that can help patients lose weight, reduce the severity of sleep apnea, and improve overall health [5]